Research Programs

-CYTONET. Development and prototyping of an innovative method for rapid differential diagnosis and rational selection of personalized treatment in inflammatory diseases based on disease-specific expression of cytokines during NETosis of peripheral blood neutrophils. EYDE-ETAK Research & Innovation Programme.
Grant no: Τ1ΕΔΚ-00617.
Duration: 9/2019-9/2022.
Total budget: 1,000,000€, ~530,000€ for DUTH partner.
Coordinator of the consortium P. Skendros. PIs of DUTH partner: P. Skendros, K. Ritis.


-BRIDGING. Novel targets for diagnostic stratification and epidemiologic surveillance of human brucellosis: host-guided molecular study in an endemic area at the crossroad between Asia and Europe. BMBF/GSRT German-Greek Bilateral Research & Innovation Programme Grant no: Τ2ΔΓΕ-0101.
Duration: 5/2018-5/2021.
Total budget: 700,000€, ~350,000€ for the Greek site.
Coordinator of the consortium & PI for the Greek partners: P. Skendros.

2011-2014: Investigation of new inflammatory mechanisms in autoinflammatory and autoimmune diseases such as Familiar Mediterranean Fever and other periodic syndroms, Gout, Crohn’s Disease, Reumatoid Arthritis and its subtypes such as Still. Collaboration research project with ITE, Crete, (ESPA 2007-2011, SYNERGASIA). 250000 Εuros for DUTH – ONGOING. (co-Supervisor: K. Ritis)

2003-2006: Networks of research and education: Molecular Medicine and Immunology- from basic research to clinical application. General Secretariat of Research and Technology, program 8.3-action 8.3.6. 144000 Euros – COMPLETED. (Supervisor: K. Ritis)

2001-2004: Research Collaboration project with Pathophysiology Department of Athens University. “The role of IRF1 in myelodysplastic syndromes”. PENED 2001, General Secretariat of Research and Technology, 52000 Euros for DUTH – COMPLETED. (co-Supervisor: K. Ritis)

2001-2003: Study of transcriptional factor IRF1 in extrapulmonary tuberculosis. 12000 Euros – COMPLETED. (co-Supervisor: K. Ritis)

2001-2003: Molecular isolation of M. Tubercolosis complex in extrapulmonary turbeculosis. General Secretariat of Research and Technology, PAVET2000, in collaboration with “ANADRASI”. 160000 Euros – COMPLETED. (Scientific Supervisor: K. Ritis)

2000-2004: Study of Interferon Regulated Trancription factors in Chronic Myeloid Leukemia. General Secretariat of Research and Technology, PENED99, 631 and PENED 2001. 105000 Euros for DUTH – COMPLETED. (co-Supervisor: K. Ritis, collaboration with ITE, Crete)

1996-1998: Application of telomeric repeats as an early index of leukemic relapse and estimation of minimal residual disease. Democritus University of Thrace, KE 404. 15000 Euros – COMPLETED. (Main Investigator: K. Ritis)

1995-1997: The role of Bruton’s Tyrosine Kinase (Btk) in the development of leukemic cell. General Secretariat of Research and Technology, PENED’95 1550. 34000 Euros – COMPLETED. (co-Supervisor: K. Ritis)

-SKIPPAIN. A 24-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of secukinumab in controlling spinal pain in patients with axial spondyloarthritis». Novartis.2018-2019, PI: P. Skendros

-Research and diagnosis of autoinflammatory and immune disorders using genetic and protein analysis. SARF (ELKE) DUTH, provision of specialized diagnostic services, grant 80895, 2016-2021. PI: K. Ritis, Sub-Investigator P. Skendros

-ENTYVIO (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with Ulcerative Colitis or Crohn’s Disease. Takeda. 2016-2021. PI: G. Kouklakis, Sub-Investigator P. Skendros

-REVOLVE. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to investigate the efficacy and safety of Mongersen (GED-0301) for the treatment of Subjects with Active Crohn’s Disease. Celgene Corporation. 2016-2018. PI: G. Kouklakis, Sub-Investigator P. Skendros

-SUSTAIN. A Phase 3, Long-term Active Treatment Extension Study of Mongersen (GED-0301) in subjects with Crohn’s disease. Celgene Corporation. 2017-2019. PI: G. Kouklakis, Sub-Investigator P. Skendros

-SPINE. Ankylosing spondylitis and Psoriatic arthritis in Greece – current epidemiology and treatment. Novartis. 2016-2017.PI: K. Ritis, Sub-Investigator P. Skendros

-ILIAD. Epidemiological features of InterLeukin-1–mediated Inflammatory diseAses and their response to current Drug treatment in Greece. Novartis. 2013-2014. PI: K. Ritis, Sub-Investigator P. Skendros

PMOS GREC 2004-7 TARKA. Safety and tolerance, efficacy of combination treatment with Verapamile/Transdolapril in the achievement of optimal arterial blood pressure in clinical practise. ABBOT LABORATORIES HELLAS 10710 Εuros – COMPLETED. (Supervisor: K. Ritis)

International study in the prevention of abdominal obesity and its correlation to cardiometabolic risk. (INSPIRE ME-PM-C-0002) SANOFI AVENTIS ΑΕΒΕ. 4760 Euros – COMPLETE. (Supervisor: K. Ritis)